Immunovant, Inc. (IMVT) NASDAQ
28.91
-0.58(-1.97%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
28.91
-0.58(-1.97%)
Currency In USD
Address
320 West 37th Street
New York City, NY 10018
United States of America (the)
Phone
917 580 3099
Website
Sector
Healthcare
Industry
Biotechnology
Employees
362
First IPO Date
June 21, 2019
| Name | Title | Pay | Year Born |
| Eric Venker | Chief Executive Officer & Director | 55,000 | 1987 |
| Frank Torti | Executive Chairperson of the Board | 92,500 | 1979 |
| Christopher Van Tuyl | Chief Legal Officer & Corporate Secretary | 549,038 | 1975 |
| Melanie Gloria | Chief Operating Officer | 575,913 | 1978 |
| Jay S. Stout | Chief Technology Officer | 683,490 | 1963 |
| Michael Geffner | Chief Medical Officer | 804,015 | 1969 |
| Tiago Girao | Chief Financial Officer | 871,065 | 1979 |
| Andy Deig | Senior Vice President of Strategic Finance | 0 | N/A |
| Christine Blodgett | Senior Vice President of Human Resources | 0 | N/A |
| Jody Roth | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Julie Kirschling | Senior Vice President of Program & Alliance Management | 0 | N/A |
| Lauren Schrier | Vice President & Head of Global Medical Affairs | 0 | N/A |
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.